SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001564590-21-056817
Filing Date
2021-11-15
Accepted
2021-11-15 08:30:32
Documents
16
Period of Report
2021-11-15
Items
Item 2.02: Results of Operations and Financial Condition
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K ktra-8k_20211115.htm   iXBRL 8-K 48141
2 EX-99.1 ktra-ex991_6.htm EX-99.1 82119
3 GRAPHIC g5mhnwbvs2fn000001.jpg GRAPHIC 5293
4 GRAPHIC g5mhnwbvs2fn000002.jpg GRAPHIC 5293
5 GRAPHIC g5tglx2amr2y000001.jpg GRAPHIC 115441
  Complete submission text file 0001564590-21-056817.txt   443998

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA ktra-20211115.xsd EX-101.SCH 5681
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ktra-20211115_lab.xml EX-101.LAB 19335
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ktra-20211115_pre.xml EX-101.PRE 11483
9 EXTRACTED XBRL INSTANCE DOCUMENT ktra-8k_20211115_htm.xml XML 3527
Mailing Address 12707 HIGH BLUFF DR., SUITE 200 SAN DIEGO CA 92130
Business Address 12707 HIGH BLUFF DR., SUITE 200 SAN DIEGO CA 92130 (858) 350-4364
Kintara Therapeutics, Inc. (Filer) CIK: 0001498382 (see all company filings)

IRS No.: 990360497 | State of Incorp.: NV | Fiscal Year End: 0630
Type: 8-K | Act: 34 | File No.: 001-37823 | Film No.: 211406575
SIC: 2834 Pharmaceutical Preparations